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Abstract
Background: We evaluated the role of CYP3A5, ABCB1 and SXR gene polymorphisms in the occurrence of acute
kidney rejection in a cohort of pediatric renal transplant recipients.
Methods: Forty-nine patients were genotyped for CYP3A5, ABCB1 and SXR polymorphisms and evaluated with
tacrolimus through levels in a retrospective monocenter study.
Results: Patients with the A allele of CYP3A5 treated with tacrolimus had a higher risk of acute rejection than those
without the A allele, while patients carrying the homozygous GG variant for SXR A7635GG did not show any
episode of acute rejection.
Conclusion: Genetic analysis of polymorphisms implicated in drug metabolism and tacrolimus trough levels may
help to forecast the risk of acute rejection and individualize drug dosage in children undergoing renal
transplantation.
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Background
Acute rejection occurs in up to 10–15% of patients during
the first year following kidney transplantation [1], and is as-
sociated with long-term allograft dysfunction. The immune
response directed against the graft is the result of either
acute cellular rejection, due to a T-cell-dependent process,
or acute humoral rejection, generated by B-cells [2–6]. Sev-
eral factors influence the occurrence of acute rejection: re-
cipient clinical and immunological characteristics
(particularly HLA donor/recipient mismatch), donor clin-
ical and biochemical data, and transplant-related factors
[7]. Potent immunosuppressive agents have significantly
increased the short- and long-term allograft and patient
survival [8, 9], but inadequate doses of immunosuppressive
drugs may be found in clinical practice, leading to clinical
or subclinical reactivation of the immune system.
Tacrolimus is the main calcineurin inhibitor used in
kidney transplantation in high-income countries [10]. It
is metabolized by cytochrome P-450, encoded by the
CYP genes cluster. It is well known that polymorphisms
of the intracellular metabolizer enzyme CYP and the
trans-membrane transport protein ABCB1 may influence
enzymatic intracellular activity, modifying drugs metab-
olism [11–19]. Patients with the A allele on CYP3A5*3
need to double the dose of tacrolimus in order to reach
therapeutic blood concentration [20]. Additionally,
ABCB1 polymorphisms may affect, either positively or
negatively, tacrolimus metabolism [21], even if to a lesser
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: stefano.turolo@policlinico.mi.it
1Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico UOC Nefrologia
Dialisi e Trapianto pediatrico, Via della, Commenda 9, 20122 Milan, Italy
Full list of author information is available at the end of the article
Turolo et al. BMC Pediatrics          (2020) 20:246 
https://doi.org/10.1186/s12887-020-02152-3
extent. The expression of both CYP and ABCB1 genes is
regulated by the intracellular receptor SXR [22, 23],
which, after activation, makes up a heterodimer with
various molecules to act as a transcriptional activator
[23]. It has been reported that SXR A7635G, an intronic
single nucleotide polymorphism (SNP), is able to in-
crease tacrolimus clearance [24, 25]. On the other hand,
studies in kidney transplant recipients showed no effect
of this SNP on tacrolimus blood concentration [26, 27].
More recently, tacrolimus through levels were corre-
lated with the risk of acute rejection during the first-year
post transplantation [28]. However, a study of genes
polymorphisms involved in the calcineurin pathway did
not find any positive correlation between the main SNPs
and acute rejection rate [29].
The aim of this retrospective study was to evaluate the
role of CYP3A5, ABCB1 and SXR polymorphisms on ta-
crolimus through levels and acute rejection rate in a




We analyzed the data of 49 children transplanted be-
tween January 2000 and December 2010 in a single
Pediatric Nephrology unit. Inclusion criteria were: age
between 1 and 18 year old, clinical and laboratory follow
up for at least 1 year, data on blood trough levels of Ta-
crolimus at 1 week, 1,3,6 months and 1 year and data on
CYP3A5, ABCB1 and SXR polymorphisms. Exclusion
criteria were simultaneous liver-kidney transplantation.
Clinical data
Tacrolimus was administered at a dose of 0.3 mg/kg/day
in order to achieve trough blood levels (C0) of 10–20
ng/ml during the first two post-transplant months and
5–10 ng/ml thereafter. The calcineurin inhibitor was ad-
ministered in combination with mycophenolate mofetil
at a starting dose of 600–800 mg/m2 /day, aiming for a
C0 of 1.5–3 μg/ml.
Steroids were given intravenously (10–15 mg/kg/day)
for the first two postoperative days and then orally at a
dose of 1 mg/kg/day, which was gradually tapered to
0.125 mg/kg/day by 6 months after transplantation.
The diagnosis of acute rejection was made on the clin-
ical and laboratory grounds, increase of more than 20%
of serum creatinine, appearance of proteinuria, and re-
duction of urinary output. The diagnosis was confirmed
by renal biopsy, according to Banff criteria [30, 31].
HLA mismatching, tacrolimus through blood levels
and gene polymorphisms of CYP3A5, ABCB1 and SXR
were analysed as risk factors of acute rejection rate.
As regards tacrolimus, whole blood sampling was per-
formed at 6, 30, 60, 180 and 360 days after transplantation
and the following pharmacological parameters were
assessed: tacrolimus trough blood level (C0: ng/ml), daily
dose per body weight (mg/kg) and dose-normalized
trough level (C0/dose/kg BW). Tacrolimus blood concen-
tration was measured using Syva® EMIT (Dade Behring,
Eschborn, Germany).
Genotyping
As regards genotyping of CYP3A5, ABCB1 and SXR
polymorphisms 500 μl of whole blood were collected
during routine ambulatory control.
DNA extraction was performed by extractor Fuji
QuickGene-810 (Fujifilm, Tokyo, Japan), PCR was car-
ried out in 20 μl of a solution containing 2 μl of 10 x
PCR Gold Buffer, 2 mM of MgCl2 (Applied Biosystem,
Foster City, CA, USA), 80 μM each of dNTPs (Euro-
clone, Pero, Milan, Italy), 50 pmol each of primers for
CYP3A and ABCB1 as previous described [32], 50 ng of
genomic DNA and 0.6 U of AmpliTaq Gold (Applied
Biosystem, Foster City, CA USA). For the polymorphism
of SXR A7635G and SXR –200 GAGAAG/− (rs3842689)
we used the following primers: SXR A7635G forward 3′-
TGG ATG CCA AGC TCA GTGG − 5′; reverse 3′-
CAG CAG CCA TCC CAT AAT CC − 5′; for SXR
rs3842689 we used the following primers pair: forward
3′-CTG ATG CTC TCT GGT CCT GC − 5′, reverse
3′-TGC CTG CTA TAG CTG ATT CAT TG-5′ with a
melt temperature of 60 °C for both polymorphisms..
The template was purified by liquid handling Biomek®
3000 (Beckman Coulter, CA, USA) using a magnetic
particles system (Agencourt/Beckman Coulter, CA,
USA). The single DNA strand was amplified by BigDye®
3.1 (Applied Biosystems, Foster City, CA USA) and then
sequenced by a 3130xl Genetic Analyzer (Applied Bio-
systems/Hitachi, Foster City, CA USA).
Statistical analysis
Data were analyzed with Mann Whitney test for
pharmacological data, and Fisher exact test for the acute
rejection data, a p-value < of 0.05 was considered signifi-
cative. All analyses ware performed with SPSS software
(IBM).
Results
Forty-nine pediatric patients who received a kidney
transplant between January 2000 and December 2010,
from either deceased (44) or living (5) donors, and who
were treated with an immunosuppressive protocol in-
cluding tacrolimus and with a complete set of tacrolimus
trough blood levels and pharmacogenomic data were
available for evaluation. Their demographic and clinical
characteristics are shown in Table 1.
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HLA mismatch
Eight patients had one episode of acute rejection during
the first year post transplantation.
Recipients’ HLA matches and mismatches are shown in
Table 2. The majority of the patients (27/49) matched the
donor HLA A, B and DR for at least one allele. Four or
five mismatches were present in 22 patients. However,
upon analyzing HLA matches/mismatches in the eight pa-
tients who had acute rejection episodes (Table 3), no cor-
relation between the occurrence of acute rejection and
HLA mismatches was apparent.
Acute rejection and SNPs
The number of acute rejection episodes in relation to
the type of gene polymorphism (CYP3A5*3, CYP3A4B,
ABCB1, SXR) is shown in Table 4. The twelve patients
with A allele polymorphism for CYP3A5 had a signifi-
cantly higher number of acute rejection episodes as
compared to the 37 with GG polymorphism (p-value <
0.05 at Fisher exact test). The nine patients homozygous
GG for SXR A7635G polymorphism did not show any
acute rejection episode, in contrast with the patients
who had rejection episodes pertaining to the cohort of
40 carriers of A allele (p-value < 0.05). No significant
correlation was found between ABCB1 polymorphisms
and rejection.
Drug trough level and genetic
Tacrolimus dose, blood trough levels and dose-
normalized trough levels of the 49 patients from 6 to 360
days after transplantation are reported in Table 5 in rela-
tion to the different gene polymorphisms. Tacrolimus
trough level (C0 normalized for dose/kg) of the 12 pa-
tients who were carriers of the A allele in CYP3A5*3 was
significantly lower than that of the 37 who were not car-
riers (homozygous GG) throughout (p-value < 0.05 at
Mann Whitney test for all considered time points). No dif-
ferences were found in tacrolimus trough level of patients
with all the other gene polymorphisms (data not shown).
Finally, considering the whole cohort of 49 patients
(Table 6), no significant difference was present as
regards tacrolimus trough levels between patients with
acute rejection episodes and those without. Conversely,
considering the eight patients with rejection episodes
(Table 7), those with the A allele for CYP3A5*3 pre-
sented with a significantly lower tacrolimus trough level
(p-value < 0.05 at Mann Whitney test) than those who
were not carriers for A allele (homozygous GG). More-
over, the five patients with A allele for CYP3A5*3 who
presented acute rejections episodes had a lower tacroli-
mus trough level in comparison to the seven who were
carriers for allele A but did not show any acute rejection
(p-value < 0.05 at Mann Whitney test).
Discussion
Several factors have been associated with the occurrence
of acute rejection episodes during the first year after
Table 1 Demographic data of the pediatric renal transplant
recipients
Variable Value
Male/female 28/21 (n = 49)
Age (Mean ± SD) 15.6 ± 6.1 (3 under 6 years of age)
Weight (Mean ± SD)
Day 7: 44.69 ± 17.87 kg
Day 30: 44.86 ± 18.00 kg
Day 90: 47.76 ± 18.7 kg
Day 180: 49.31 ± 18.66 kg











CAKUT = Congenital Abnormalities of the Kidneys and the Urinary Tract
Table 2 Frequency of HLA allele mismatches in all 49 patients







Table 3 HLA hetero and homozygous match/homozygous
mismatch in the 8 patients who had acute rejection (AR)
episodes
HLA A HLA B HLA DR Match/mismatch
Patient 1 Match Match Match 3/0
Patient 2 Match Match Match 3/0
Patient 3 Match Match Match 3/0
Patient 4 Match Mismatch Mismatch 1/2
Patient 5 Match Match Match 3/0
Patient 6 Match Match Match 3/0
Patient 7 Match Mismatch Match 2/1
Patient 8 Match Match Mismatch 2/1
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renal transplantation, namely the number of HLA mis-
matches, a low immunosuppressive drug blood concen-
tration and, more recently, a series of gene
polymorphisms [7, 28].
In our population, HLA mismatch did not seem to
play a significant role in determining acute rejection rate
(Table 3). Additionally, HLA mismatch had no signifi-
cant role in the occurrence of acute rejection in a recent
report by Parajuli et al., who analyzed 1102 kidney
biopsies and did not find any correlation between the
HLA mismatch and the risk of acute rejection [33].
The role of changes in drug metabolism, induced by
polymorphisms of a number of genes, has been repeat-
edly underlined in the last two decades [11–19].
In particular, blood concentration of immunosuppres-
sive drugs has a pivotal role in preventing acute rejection
and allograft failure. Therapeutic tacrolimus blood con-
centration is particularly important during the first 3
Table 4 Number of acute rejection episodes in relation to the different gene polymorphisms
GENE polymorphism N° of acute rejection episodes
CYP3A5 AG (n = 12) (24.4%) 5* (41.6%)
GG (n = 37) (75.5%) 3 (1.0%)
CYP3A4B AA (n = 43) (87.7%) 7 (16.2%)
AG (n = 6) (12.2%) 1 (16.6%)
SXR A7635G AA (n = 16) (32.6%) 2 (12.5%)
AG (n = 24) (48.9%) 6 (25.0%)
GG (n = 9) (18.3%) 0* (0.0%)
SXR RS rs3842689 In/in (n = 19) (38.7%) 3 (12.9%)
In/del (n = 22) (44.8%) 4 (18.1%)
Del/del (n = 8) (16.32%) 1 (12.5%)
ABCB1 C1236T CC (n = 18) (36.7%) 3 (16.6%)
CT (n = 19) (38.7%) 2 (10.5%)
TT (n = 12) (24.4%) 3 (0.25%)
ABCB1 G2677T/A GG (n = 16) (32.6%) 2 (12.5%)
GT/A (n = 26) (53.0%) 5 (19.2%)
TT (n = 7) (14.2%) 1 (14.2%)
ABCB1 C3435T CC (n = 15) (30.6%) 4 (26.6%)
CT (n = 24) (48.9%) 2 (8.3%)
TT (n = 10) (20.4%) 2 (20.0%)
* p-value < 0.05 at Fisher exact test
Table 5 Tacrolimus pharmacokinetic data in relation to CYP3A5 and SXR A7635G gene polymorphisms in the 49 patients of the
study
Days CYP3A5*3 SXR A7635G
AA/AG (12 patients) GG (37 patients) AA (16 patients) AG (24 patients) GG (9 patients)
Dose/kg (mg/kg) day 7 0.17 ± 0.10 0.15 ± 0.06 0.18 ± 0.10 0.14 ± 0.04 0.16 ± 0.06
day 30 0.18 ± 0.10 0.13 ± 0.06 0.17 ± 0.11 0.14 ± 0.05 0.14 ± 0.07
day 90 0.15 ± 0.09 0.11 ± 0.06 0.14 ± 0.10 0.10 ± 0.05 0.12 ± 0.07
day 180 0.13 ± 0.08 0.09 ± 0.06 0.11 ± 0.09 0.08 ± 0.04 0.11 ± 0.07
day 360 0.11 ± 0.08 0.07 ± 0.05 0.10 ± 0.08 0.07 ± 0.03 0.08 ± 0.07
C0/(dose/kg) (ng/ml)/(mg/kg) day 7 67.52 ± 48.67* 80.67 ± 58.46 95.47 ± 82.73 64.13 ± 24.06 79.11 ± 53.07
day 30 73.83 ± 105.88* 111.45 ± 70.37 103.21 ± 87.98 97.40 ± 60.02 111.86 ± 118.66
day 90 92.19 ± 139.61* 114.52 ± 68.18 103.33 ± 76.67 108.79 ± 64.90 119.26 ± 157.82
day 180 70.48 ± 137.70* 137.70 ± 103.44 121.30 ± 101.09 127.20106.22 104.06 ± 70.10
day 360 72.56 ± 182.92* 182.92 ± 199.75 192.34 ± 283.35 142.93 ± 103.30 121.24 ± 78.97
Data are expressed as mean ± S.D. * p-value < 0.05 at Mann Whitney test
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months after transplantation [34] and a wide therapeutic
window, from 5 to 9.5 ng/ml, is warranted during the
first-year post transplantation [35]. To elucidate, the pre-
scription of an adequate tacrolimus dose since the early
post-transplant days is considered to be of the upmost im-
portance [36]. Likewise, Hu et al., suggested a positive re-
lation between the time needed to reach a therapeutic
tacrolimus trough level and the occurrence of acute rejec-
tion. This relation is unique for each recipient and helps
explain why in some cases acute rejection occurs despite
tacrolimus being within the therapeutic range [37].
The importance of CYP3A5*3 gene polymorphism in
affecting the bioavailability of tacrolimus, already sug-
gested by our group [20], is confirmed by the pharmaco-
kinetic data of this study (Tables 5 and 7). Our results
also suggest that being a carrier of allele A for CYP3A5
is not the only risk factor to be considered for the pre-
vention of acute rejection, and that other factors may
counterbalance its negative effect.
To explain further, the most interesting result of this
study concerns the putative protective role of SXR A7635G
homozygous GG polymorphism against acute rejection,
which is the first report of a protective polymorphism in
the immunology of kidney rejection.
Only a few studies about SXR gene polymorphism and
rejection have been published so far. Two articles reported
that subjects homozygous GG for SXR A7635G had an in-
crease in the CYP and ABCB1 expression [38, 39] and con-
sequently, a low tacrolimus area under the curve [24–26].
In our study we did not find any positive correlation be-
tween the above cited SXR polymorphism and tacrolimus
trough level (Table 5).
It can be argued that that the SXR protective effect
does not result from an interference of the SXR poly-
morphism with the metabolism of tacrolimus, but rather
from a possible suppression of the rejection mechanism
itself, working upstream of the drug metabolic pathway
[22, 23]. In fact, SXR makes a heterodymer with the
Table 6 Tacrolimus pharmacokinetic data and occurrence of acute rejection (AR) in the 49 patients of the study
Days No AR (41 patients) AR (8 patients)
Dose/kg (mg/kg) day 7 0.17 ± 0.08 0.13 ± 0.03
day 30 0.15 ± 0.08 0.15 ± 0.06
day 90 0.11 ± 0.08 0.11 ± 0.08
day 80 0.09 ± 0.07 0.10 ± 0.04
day 360 0.07 ± 0.06 0.08 ± 0.04
C0/(dose/kg) (ng/ml)/(mg/kg) day 7 78.07 ± 45.55 100.51 ± 89.31
day 30 115.22 ± 86.70 72.48 ± 42.91
day 90 115.37 ± 97.21 91.56 ± 49.57
day 180 130.45 ± 102.76 90.36 ± 64.71
day 360 190.11 ± 196.61 98.31 ± 51.3
Data are expressed as mean ± s.d. Mann Whitney was used as statistical test
Table 7 Tacrolimus pharmacokinetic data in relation to CYP3A5 gene polymorphisms in the 8 patients with acute rejection (AR)
Days AA/AG with AR (5 patients) GG with AR (3 patients) AA/AG without AR
(7 patients)
Dose/kg (mg/kg) day 7 0.14 ± 0.01 0.11 ± 0.05 0.19 ± 0.14
day 30 0.20 ± 0.03* 0.09 ± 0.03 0.18 ± 0.13
day 90 0.14 ± 0.05* 0.08 ± 0.01 0.16 ± 0.12
day 80 0.13 ± 0.04* 0.06 ± 0.01 0.14 ± 0.10
day 360 0.10 ± 0.04 0.05 ± 0.02 0.13 ± 0.10
C0/(dose/kg) (ng/ml)/(mg/kg) day 7 55.56 ± 20.87 175.42 ± 120.49 74.92 ± 62.45
day 30 45.81 ± 10.91 *# 105.81 ± 47.40 92.53 ± 49.62
day 90 63.92 ± 26.57*# 126.11 ± 54.57 110.56 ± 55.25
day 180 55.33 ± 23.42* 134.14 ± 77.98 79.78 ± 35.21
day 360 79.48 ± 49.34 121.85 ± 50.87 66.35 ± 37.25
Data are expressed as mean ± s.d. Mann Whitney was used as statistical test
* p-value < 0.05 AA/AG vs GG patients with acute rejections
# p-value < 0.05 AA/Ag with acute rejection vs AA/AG without acute rejection
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protein HSP90, a chaperonine that is involved in acute
rejection, and binds to FKBP5, a protein of the same
family of the tacrolimus target protein [40–42]. Conse-
quently, the interaction between SXR and HSP90-
FKBP5 may interfere with the acute rejection
mechanism.
According to our data, both pre-transplantation genetic
screening for SXR A7635G and CYP3A5*3 polymorphisms
and post-transplantation drug monitoring could help in
preventing an ineffective tacrolimus trough level by identi-
fying the carriers of either protective or risk factors.
A limitation of this study is the relatively low number of
patients for each evaluated cohort, in particular of patients
GG for SXR A7635G. However, these numbers are similar to
those of other pediatric articles on the same topic [43, 44].
Conclusion
In conclusion, this study, along with the other retro-
spective studies [45, 46], demostrate the importance of
pharmacokinetics and pharmacogenomics to decrease
the occurrence of acute rejection, however, there still re-
main several barriers to their routine clinical application
[46]. Pharmacogenomics of tacrolimus can drive the
clinical decision regarding the starting dose, with a bene-
fit for the transplanted patients, as it was previously de-
scribed [46]. Even if pharmacogenetics suffer from some
grade of imprecision, due to the interaction of various
polymorphisms, in the case of tacrolimus it should be
performed together with the classical therapeutic drug
monitoring, which is able to reduce the inter-individual
pharmacokinetic variability.
In this way, the genetic analysis for CYP3A5*3 and
SXR A7635G polymorphisms, performed in advance of
transplantation, may be of help in forecasting the risk of
acute rejection and in choosing the appropriate tacroli-
mus dosage for each individual patient in the first year
after kidney transplantation.
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